

Randomized Double-Blind Placebo-Controlled Trial Evaluating Baricitinib on PERSistent NEurologic and Cardiopulmonary Symptoms of Long COVID

NCT06631287

Status	RECRUITING
Phase	Phase 3
Sponsor	Wes Ely
Enrollment	550 participants

Key Eligibility Criteria

Inclusion (25)

- In order to be eligible to participate in this investigation, an individual must meet all of the following criteria:
 - Cohort #1 (n=500):
 - Evidence of personally signed and dated informed consent document indicating that the participant has been informed of all pertinent aspects of the study and was willing and able to consent to participation.
 - Age e18 years old.
 - Documented SARS-CoV-2 infection 6 or more months prior to screening, confirmed with acceptable documentation that includes (at minimum) their name, the date the test was taken (must be after January 2020), and details specifying that the positive test was for SARS-CoV-2 infection.
- ... and 20 more (see full listing online)

Exclusion (39)

- An individual who meets any of the following criteria will be excluded from participation in this investigation:
 - Qualifying Long COVID symptoms cannot be explained by an infection-associated chronic condition diagnosed prior to the onset of Long COVID (e.g., ME/CFS or other infection-associated chronic condition).
 - Pre-existing cognitive impairment not exacerbated by COVID-19, including but not limited to syphilis, as determined by study clinicians (MD, DO, NP, PA, RN, or equivalent), which may include a review of participant's history and medical records.
 - Severe cognitive, physical, or psychological disability preventing participation in the study, as determined by the investigator.
 - Moderate or High risk of suicidality, as determined by the modified Columbia Suicide Severity Rating Scale (mC-SSRS).
- ... and 34 more (see full listing online)

Locations (16 total)

University of Arizona, Tucson, Arizona, United States
University of California, Los Angeles (UCLA), Los Angeles, California, United States
University of California San Francisco, San Francisco, California, United States
... and 13 more locations